Interim Report January-March 2014 Chrontech Pharma AB

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

· Research and development costs amounted to SEK 0.4 (0.0) m
· Loss after tax was SEK -1.4 (-1.5) m
· Earnings per share were SEK -0.01 (-0.01)
· The company had no net sales for the period
· ChronTechs therapeutic hepatitis D vaccine activates an immune response that can enter the liver and eliminate liver cells that produce parts of HDV

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC